Post

New research · Ophthalmology
Theranostics · 2d
Animal / preclinicalTheranostics · 2026

Localized and sustained release of Botulinum Toxin A from supramolecular peptide hydrogel for strabismus treatment.

Wei Guo, Hui Zhu, Yuchen Yao … Hu Liu
Read paper
OphthalmologyAnimal / preclinical

Peptide hydrogel delivery boosts local retention of botulinum toxin A near injection site.

Localized and sustained release of Botulinum Toxin A from supramolecular peptide hydrogel for strabismus treatment.

Wei Guo … Hu Liu
Theranostics · 2026
Background

Botulinum toxin type A (BTXA) is an injectable neurotoxin widely used for the nonsurgical treatment of strabismus.

Methods

In this research, we co-assembled a pentapeptide hydrogelator Nap-Phe-Phe-Lys-Lys-Lys (NapFFKKK) with BTXA under mild physiological conditions to form a supramolecular hydrogel Gel Nap+BTXA for localized and sustained release of BTXA.

3.1-fold
Results
3.1-fold
Hydrogel delivery kept far more toxin concentrated at the muscle injection site.
More results

Furthermore, Gel Nap+BTXA effectively alleviated ptosis and provided more stable and long-lasting ocular alignment correction up to 2 months, with no detectable ocular or systemic toxicity.

“
Conclusion

This study demonstrated a safe and efficient localized delivery strategy for BTXA, offering a promising alternative for strabismus treatment.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
0·962 for OCT
MerMED-FM was very accurate at diagnosing diseases using eye scans
AI / Informatics
0.98
Artificial intelligence's eyelid-height measurements matched doctors' manual measurements almost perfectly
AI / Informatics
92.1%
combining eye scans and photos correctly told benign from cancerous lesions apart nearly every time
Cohort Study
28.6%
recurred locally in more than 1 in 4 patients over years of follow-up
Cohort Study
-0.395
excision group's post-op eyelid fullness score was lower - greater improvement
Cohort Study
86.7%
of infants probed after 12 months still had unresolved tear duct blockage
Observational
16%
eyelid tissue in rosacea patients showed less of this key repair-signaling protein inside cell nuclei
Cohort Study
25%
about 1 in 4 treated cases had symptoms return after improving